PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
2008
60
LTM Revenue n/a
LTM EBITDA n/a
$20.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PolyPid has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, PolyPid achieved revenue of n/a and an EBITDA of -$26.4M.
PolyPid expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See PolyPid valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | n/a | n/a | XXX | XXX | XXX |
Gross Profit | n/a | n/a | XXX | XXX | XXX |
Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
EBITDA | -$20.4M | -$26.4M | XXX | XXX | XXX |
EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
Net Profit | -$39.6M | -$23.9M | XXX | XXX | XXX |
Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
Net Debt | $3.0M | $5.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, PolyPid's stock price is $3.
PolyPid has current market cap of $26.0M, and EV of $20.0M.
See PolyPid trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$20.0M | $26.0M | XXX | XXX | XXX | XXX | $-4.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, PolyPid has market cap of $26.0M and EV of $20.0M.
PolyPid's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate PolyPid's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for PolyPid and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $20.0M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | XXX | XXX |
EV/EBITDA | -0.8x | XXX | XXX | XXX |
P/E | -0.9x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPolyPid's NTM/LTM revenue growth is Infinity%
PolyPid's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.5M for the same period.
Over next 12 months, PolyPid's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate PolyPid's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for PolyPid and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | n/a | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | 30% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PolyPid acquired XXX companies to date.
Last acquisition by PolyPid was XXXXXXXX, XXXXX XXXXX XXXXXX . PolyPid acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was PolyPid founded? | PolyPid was founded in 2008. |
Where is PolyPid headquartered? | PolyPid is headquartered in United States of America. |
How many employees does PolyPid have? | As of today, PolyPid has 60 employees. |
Who is the CEO of PolyPid? | PolyPid's CEO is Ms. Dikla Czaczkes Akselbrad. |
Is PolyPid publicy listed? | Yes, PolyPid is a public company listed on NAS. |
What is the stock symbol of PolyPid? | PolyPid trades under PYPD ticker. |
When did PolyPid go public? | PolyPid went public in 2020. |
Who are competitors of PolyPid? | Similar companies to PolyPid include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of PolyPid? | PolyPid's current market cap is $26.0M |
Is PolyPid profitable? | Yes, PolyPid is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.